The full activation of p53 in response to DNA damage requires the activity of the ATM and CHK2 kinases, both of which are mutated in cancer predisposition syndromes, as well as many sporadic cancers (Hafner et al., 2019; Abuetabh et al., 2022; Smith et al., 2020). Here, TP53 is linked to cancer.